Statement: The Exemestane group in the primary trial had a better median Progression-Free Survival than the Abiraterone Acetate + Prednisone group, however the patient with the maximum PFS was in the Abiraterone Acetate + Prednisone group.
Primary_evidence: Outcome Measurement:    Progression-Free Survival (PFS)   Progression-free survival was defined as the time from randomization to first occurrence of disease progression (either radiographic or clinical), or death from any cause. PFS was determined using radiographic progression defined by Response Evaluation Criteria in Solid Tumors (RECIST) on measurable lesions captured by computed tomography (CT) or magnetic resonance imaging (MRI). Clinical disease progression was considered only when disease progression could not be confirmed by CT or MRI, such as when the disease site is skin, bone marrow, or central nervous system.   Time frame: Approximately 2 years Results 1:    Arm/Group Title: Exemestane   Arm/Group Description: Participants received exemestane tablet as oral dose of 25 milligram (mg) per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).   Overall Number of Participants Analyzed: 102   Median (95% Confidence Interval)   Unit of Measure: Months  3.68        (1.94 to 5.26) Results 2:    Arm/Group Title: Abiraterone Acetate + Prednisone   Arm/Group Description: Participants received abiraterone acetate tablet at a total oral dose of 1000 milligram (mg) along with 5 mg capsule of prednisone/prednisolone per day in 28-day treatment cycles until disease progression, unacceptable toxicity, or death (up to 3 years).   Overall Number of Participants Analyzed: 89   Median (95% Confidence Interval)   Unit of Measure: Months  3.65        (2.73 to 5.59)